In this study, ELISA verified that STAT5B levels were increased significantly in the MCI group and AD group compared with the normal cognition control group, consistent with the trends observed in previous studies, suggesting that STAT5 plays an important role in the progression of cognitive disorders, and its blood level can be used as a potential biomarker for diagnosis and treatment. Here, STAT5B is linked to Alzheimer disease.